Harbour BioMed, a newly established cancer therapies company based in Shanghai, today announced it has bought Harbour Antibodies BV for cash and an equity stake in Harbour Biomed in order to form a new oncology biotech.

The acquisition was financed by Harbour BioMed investors, Advantech Capital and Legend Capital, two leading China-focused investors with a particular emphasis on life sciences.

Harbour BioMed was established in 2016 with an initial financing of USD 50m from Advantech Capital, Legend Capital and the Harbour BioMed founding team. The company is headquartered with R&D operations in Shanghai, business operations in Cambridge, MA, and antibody platform innovation operations in Rotterdam, The Netherlands. The company plans to expand its presence in the Boston area by establishing a drug discovery innovation center.

Houthoff Buruma assisted Erasmus MC Holding B.V., Atlas Holding Fund IX Coöperatief U.A. and the other shareholders of Harbour Antibodies B.V.
Houthoff Buruma team included: Bram Caudri , Joram van den Berg , Philip van der Eijk , Luke van de Laar , Philippe König , Ageeth Panman